Game changing cancer medicines now within reach for 2,200 Australians

Doctors and lung cancer campaigners are welcoming the Australian Government Federal Health Minister’s announcement that from 1 December, KEYTRUDA will be included on the Pharmaceutical Benefits Scheme for eligible patients with advanced non-small cell lung cancer in a mixture with chemotherapy irrespective of whether they have a biomarker marker called PD-L1.

Department of Health, 20/11/19